Linear Clinical Research
Linear Clinical Research
Nedlands, Western Australia, Australia23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | Disease Attributes, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Thoracic Neoplasms, adenocarcinoma, adenoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, connective tissue neoplasm, epithelial neoplasm, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, pleural neoplasm, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, sarcoma, small cell lung carcinoma, synovial sarcoma | Recruiting | Phase 1 | 2026-10-01 | NCT07713732 | |
| IKS014 in Advanced Solid Tumors That Express HER2 | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, skin disorder, stomach disorder | Recruiting | Phase 1 | 2026-09-28 | NCT05872295 | |
| Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2026-09-23 | NCT04662255 | |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-09 | NCT06854653 | |
| ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 1 | 2026-09-09 | NCT06597721 | |
| Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-09-03 | NCT06343402 | |
| Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension | cardiovascular disorder, essential hypertension, hypertensive disorder, vascular disorder | Active, not recruiting | Phase 1 | 2026-09-03 | NCT06205628 | |
| Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 1 | 2026-08-12 | NCT07285122 | |
| Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 | 2026-07-22 | NCT04603001 | |
| A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE) | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, systemic lupus erythematosus | Recruiting | Phase 1 | 2026-07-16 | NCT06917742 | |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-30 | NCT06162221 | |
| A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, skin disorder, uterine disorder | Active, not recruiting | Phase 1 | 2026-06-22 | NCT04188548 | |
| ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, neoplasm | Recruiting | Phase 1 | 2026-06-08 | NCT07238075 | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, biliary tract disorder, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-29 | NCT04956640 | |
| Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors | Adnexal Diseases, Biliary Tract Neoplasms, Carcinoma, Ovarian Epithelial, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, biliary tract disorder, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cholangiocarcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal adenocarcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, transitional cell carcinoma, uterine disorder | Recruiting | Phase 1 | 2026-05-20 | NCT07334119 | |
| Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma | B-cell neoplasm, Blood Protein Disorders, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, follicular lymphoma, hematologic disorder, hemorrhagic disease, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative syndrome, malignant histiocytosis, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-05-04 | NCT07249905 | |
| Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | Neoplasms by Histologic Type, adenoma, epithelial neoplasm, mesothelial neoplasm, mesothelioma, neoplasm, non-small cell lung carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-04-02 | NCT04665206 | |
| Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-04-01 | NCT05862012 | |
| SNV4818 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-03-13 | NCT06736704 | |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Select Advanced Solid Tumors | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-06 | NCT04262466 | |
| An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). | neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-02-10 | NCT06634849 | |
| A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, disease, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 / Phase 2 | 2025-11-24 | NCT07244705 | |
| A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | non-small cell lung carcinoma | Active, not recruiting | Phase 1 | 2025-11-24 | NCT05117476 |